Gini Harrison

Senior Lecturer @OU_Psychology. Interests: mental health & wellbeing, perinatal anxiety, psycho-oncology, eHealth, and applied cognitive psychology.

[EGFR Positive Lung Cancer UK @EgfrUk]

Scotland has today approved amivantamab + chemotherapy as a first-line treatment for adults with advanced #lungcancer caused by EGFR Exon 20 insertion mutations.

The PAPILLON trial showed this combination helps people stay on treatment for longer before the cancer grows again.

This applies to people who haven’t started treatment yet. It’s Scotland-only for now. Decisions for England & Wales are still to come. #Exon20 #LCSM

[Sky Sports Cricket @SkyCricket]

Anushka Karmalkar and Jim Carter speak about how the @RuthStraussFdn helps families affected by incurable cancer ❤️

#RedForRuth

[CancerTherapyAdvisor @CancerTherAdvsr]

Osimertinib after definitive chemoradiotherapy is a "new standard of care" in unresectable, stage III, EGFR-mutant NSCLC, reported @RamalingamMD of @WinshipAtEmory in an updated analysis of the LAURA study presented at #ELCC25. #ELCC2025 #lcsm

[Noemi Reguart @NReguart]

Osimertinib BEATEN!! MARIPOSA (Ami + Lazer) shows significant OS (HR 0.75, p<0.005, 3yr 60% vs 51%) and landmark 3-yr icPFS improvement (36% vs 18%)—first combo to show OS superiority over SoC, extending OS beyond 3 years in 1L EGFRm NSCLC. #ESMOAmbassadors #ELCC25 @myESMO

[Gini Harrison @GiniHarrison]

Genuine goosebumps. I wish she would run. I have cast my vote… let’s hope people listen to her. 🤞🏻

[Alex Cole @acnewsitics]

Michelle Obama really hit this one out of the park! If there is anything you watch today make sure it's this!

[Stephen V Liu, MD @StephenVLiu]

#ESMO24 @DrSanjayPopat presents an interim OS update for MARIPOSA-2 (amivantamab + chemotherapy vs chemotherapy in #EGFR mutant NSCLC post osimertinib). OS trend favors adding amivantamab (HR 0.73), not yet statistically significant. 18m OS rate 50% vs 40%. #ESMOAmbassadors

[Yvonne Diaz @Yvonne_Diaz_]

Prof @CharlesSwanton finds use of ctDNA in operable #lungcancer determines relapse at #ESMO24. Positive pre-operative ctDNA predicts odds of relapse.

Should ctDNA use be standard in all operable cases? Will this inform treatment in future esp those w pre-operative ctDNA?

[Gini Harrison @GiniHarrison]

RT @EgfrUk: Our Research Trustee, Gini Harrison, talking about the real challenges of managing skin issues caused by #EGFR treatments & how…

[Eric K. Singhi, MD @lungoncdoc]

Lung cancer: Why non-smokers don't respond to treatments via ⁦@mnt⁩

“All you need to be at risk for lung cancer is to have lungs,” Singhi told Medical News Today ⁦⁦
https://t.co/cPSgIM1xJ9

[Gini Harrison @GiniHarrison]

@DrSanjayPopat @BTOGORG This is a huge blow for UK-based #Exon20 patients like me. Particularly as Mobo was found to be as effective as chemo in EXCLAIM-2... it just failed to show superiority over it. EXCLAIM-1 already demonstrated efficacy beyond 1st line. So its withdrawal is devastating!

[Gini Harrison @GiniHarrison]

@SuyogCancer But why? EXCLAIM-2 just failed to show *superiority* over chemo in 1st line treatment. It was still as effective as chemo... This withdrawal is a HUGE blow for #Exon20 patients like me. Particularly in the UK, where Mobo was our only NHS Exon20 drug.

[Gini Harrison @GiniHarrison]

@KatsuakiMaehara @EGFRResisters @OncoAlert It didn't though-it just failed to show superiority over chemo in 1st line treatment. It was as effective as chemo... & effective beyond 1st line. So this withdrawal is a HUGE blow for #Exon20 patients like me. Particularly in the UK, where Mobo was our only NHS Exon20 drug.

[Sanjay Popat @DrSanjayPopat]

This is big news for UK. Mobocertinib is the only reimbursed ex20 inhibitor we have (post platinum) and its withdrawal will leave a big void until other agents get licensed and reimbursed @BTOGORG

[Exon 20 Group, a multistakeholder organization @Exon20Group]

Dark day for #EGFR #exon20 pts when discussions betw. @FDAOncology & @TakedaOncology led to a decision re #mobocertinib's withdrawal (timing unclear). No words! We've worked w/mobo since early 2017 & need it to be available as one of our 2 anchor drugs. 844-662-8532 (Takeda info)

[Gini Harrison @GiniHarrison]

@maraantonoff @MDAndersonNews @IASLC I’m an oligometastatic NCSLC Exon 20 patient. I was offered LCT in the form of chemoradiation in 2021, which has so far proved pretty successful. But if I had been offered surgery, I would have jumped at the chance. Still would! Thanks for highlighting this as a viable pathway!

[Gini Harrison @GiniHarrison]

@hannahmary8890 Haha… yup! The episode Baby Race almost killed me when I first watched it. I will also happily watch it without any children in the room. Bluey is just brilliant!

[Gini Harrison @GiniHarrison]

Evidence for the effectiveness of online cognitive behaviour therapy in supporting perinatal mental health. Please share: https://t.co/0uCNEkxQkk

[Gini Harrison @GiniHarrison]

@hannahmary8890 Thank you so much for posting this. It is so, so important to normalise talking about the tough times in parenting. The social media “highlight reel” usually only shows the good times-and my goodness, the hard times are hard! So thank you for your honesty. :)

[Gini Harrison @GiniHarrison]

@RNGebhardt @DianaSm18590505 @EM_RESUS Ummm… that’s 4 countries. Not 3.

[Gini Harrison @GiniHarrison]

@CRUKresearch Thank you for having us!! It was a privilege to be involved, to represent patient voice and discuss patient involvement in research, from both an academic and personal perspective.